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Abstract
Background: Bowel cancer is common and a major cause of death. The NHS is currently rolling out a
national bowel cancer screening programme that aims to cover the entire population by 2010. The
programme will be based on the Faecal Occult Blood test (FOBt) that reduces mortality from colon cancer
by 16%. However, FOB testing has a relatively low positive predictive value, with associated unnecessary
cost, risk and anxiety from subsequent investigation, and is unacceptable to a proportion of the target
population. Increased levels of an enzyme called matrix metalloproteinase 9 (MMP9) have been found to
be associated with colorectal cancer, and this can be measured from a blood sample. MMP9 has potential
for detecting those at risk of having colorectal cancer. The aim of this study is to assess whether MMP9
estimation enhances the predictive value of a positive FOBt.
Methods and design: FOBt positive people aged 60–69 years attending the Wolverhampton NHS Bowel
Cancer Screening Unit and providing consent for colonoscopy will be recruited. Participants will provide
a blood sample prior to colonoscopy and permission for collection of the clinical outcome from screening
unit records. Multivariate logistic regression analyses will determine the independent factors (patient and
disease related, MMP9) associated with the prediction of neoplasia.
Discussion: Colorectal cancer is a major cause of morbidity and mortality. Pilot studies have confirmed
the feasibility of the national cancer screening programme that is based on FOBt. However, the test has
high false positive rates. MMP9 has significant potential as a marker for both adenomas and cancers. This
study is to examine whether using MMP9 as an adjunct to FOBt improves the accuracy of screening and
reduces the number of false positive tests that cause anxiety and require invasive and potentially harmful
investigation.
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About one in 20 people in the UK will develop colorectal
cancer during their lifetime [1]. It is the third most com-
mon cancer in the UK, and the second leading cause of
cancer death, with over 15,000 people dying from color-
ectal cancer each year [2]. Colorectal cancer incurs an
annual expenditure of more than £300 million in surgi-
cal, adjuvant, and palliative treatment [3]. As the popula-
tion ages these costs are set to increase. Reduced costs of
treatment could be achieved by earlier diagnosis. How-
ever, most cases are diagnosed at a late stage which is
strongly associated with poorer survival; the five year
overall survival rate of colorectal cancer is only 48% [4].
Benefits, in terms of improved survival, improved quality
of life and reduced treatment costs, could be accrued by
earlier diagnosis.
FOBt screening can detect colorectal cancer at an early
stage when treatment is more likely to be effective. It also
provides an opportunity to identify precursors to invasive
disease, polyps, which can be removed during colonos-
copy and reduce the risk of colorectal cancer developing.
Randomised controlled trials suggest that colorectal
screening has the potential to reduce colorectal cancer
mortality by 16% [5]. In the light of the evidence from
these trials the NHS has introduced a national bowel can-
cer screening programme [6]. The first UK bowel cancer
screening site started screening men and women aged 60–
69 years in July 2006 and national coverage is expected to
be achieved by 2010. The programme uses the Faecal
Occult Blood test (FOBt). Participants in screening, who
have a positive FOBt, are then invited for colonoscopy.
Pilot evaluations, in Scotland and Rugby, confirmed the
feasibility of the national screening programme; however,
they also demonstrated relatively low acceptability of
FOBt with uptake rates of only 58.5%[7] and 52% [8] in
the first and second rounds of screening respectively.
Recent results from the NHS Bowel Cancer screening pilot
studies demonstrate that, FOBt testing has a sensitivity of
57.7%, with a positive predictive value of 5.3% for cancer
and 38.8% for neoplasia [8]. The low positive predictive
value means that although all FOBt positive results
require investigation via colonoscopy, many of these are
false positive results with the associated cost, risk and anx-
iety. Colonoscopy carries a risk of bowel perforation of 1
in 1,500 [9].
Therefore, although FOBt screening is likely to reduce the
mortality attributable to bowel cancer there is an urgent
need to improve the screening test, ideally to increase the
positive predictive value. Serum matrix metalloproteinase
9 (MMP9) are proteolytic enzymes that are associated
with tissue remodelling in normal and pathological proc-
esses [10]. Over-expression of MMP9s has been correlated
with progression in many tumour types, including color-
ectal cancer [11-13]. Our pilot suggests that MMP9 has
potential in detecting those at risk of having colorectal
cancer as it demonstrates a high specificity and positive
predictive value [11].
Pilot work
A pilot study of 300 patients attending the Queen Eliza-
beth Hospital colorectal clinic was performed. Twenty
seven significant adenomas and 63 malignancies were
identified in the study population. Patients had a stand-
ard assessment, by proforma-led history and examina-
tion, with rigid sigmoidoscopy to the recto-sigmoid
junction. The patients gave serum samples for analysis,
and referral for specialist investigations occurred as per
the clinic-protocol. Forty-six "normal" volunteers also
donated serum. ELISAs were done on each serum sample,
and the results were compared with the clinical diagnosis.
The median sMMP9 concentration was 443 ngml-1. The
model accurately predicted neoplasia in 77.3% of cases
(sensitivity 77.9%, specificity 77.1%, positive predictive
value (PPV) 44.6%, and negative predictive value (NPV)
95.8%) in a population with 30% prevalence of disease
[11].
The results of this pilot suggest that MMP9 may be an
effective secondary screening test, but this study was com-
pleted in a selected population. The performance of a
diagnostic test can vary in populations with different
severity and prevalence of disease and, therefore, the
acceptability and accuracy of MMP9 needs to be estab-
lished in the target population [14].
Study aim
The aim of the study is to assess whether the addition of
MMP9 testing enhances the predictive value of a positive
FOBt.
Methods
Study design: evaluation of a diagnostic test.
Setting: Wolverhampton NHS Bowel Screening Unit
Subjects: Participants in the NHS Bowel Cancer Screening
Programme who are FOBt positive and attending for
colonoscopy.
Those consenting to colonoscopy will be given a patient
information leaflet about the study. Prior to colonoscopy,
all those expressing an interest, will be seen by a member
of the research team who will answer any outstanding
questions and seek consent.
Intervention: Participation will entail the provision of a
blood sample prior to colonoscopy, completion of a base-Page 2 of 4
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tion of symptoms) and permission for data collection
(final diagnosis) from screening unit records.
A trained nurse/phlebotomist will take two blood sam-
ples (10 ml) to enable MMP9 determination and for a
routine haematology profile: Haemoglobin (Hb), Whole
blood cell count (WBC) and Red cell count (RCC). Blood
samples will be kept on ice and spun within 4 hours of
collection. Local storage will be at -80C until transported
to the Department of Cancer Studies, University of Bir-
mingham, for analysis.
Outcomes assessment: diagnosis collected from screening
office records. A technician, blinded to the symptoms,
signs, or diagnosis of the patient, will determine MMP9
levels by ELISA. Duplicate determinations will be per-
formed upon coded samples.
Procedures for handling data
All electronic data will be processed using password pro-
tected systems and paper data will be stored securely in
locked cabinets/rooms. Participant identification num-
bers will be employed to enable separate storage/process-
ing of name and address data. Identifiable data will be
handled only by University of Birmingham staff working
on this study who are trained in policies and procedures
related to confidentiality.
Sample size estimation
In a 12 month period, 200 people are expected to have a
positive FOBt as part of the screening programme and be
referred to Wolverhampton Screening Centre.
Our pilot data indicates that elevated MMP9 has a high
sensitivity and negative predictive value. The potential of
measuring MMP9 in FOBt positive people will be to
reduce the number of unnecessary colonoscopies i.e. a
high NPV is required. The pilot data indicated that 126
test negative patients are needed to detect a NPV of 95%
with 5% precision and 2-sided alpha of 1%. Based on this
data, a total of 209 patients are required to enable 91%
and of 31% prevalence.
Analyses
Patients will be classified into high risk (invasive adeno-
carcinoma or high risk polyps) and lower risk diagnostic
groups. The association between possible risk factors and
diagnosis will be determined based on odds ratios (OR).
Multivariate logistic regression analyses will determine
the independent factors for prediction of high risk disease
excluding MMP9 and provide adjusted OR accordingly.
The influence of MMP9 will then be assessed by the addi-
tion of MMP9 to the derived logistic regression model.
Accuracy and comparison of the predictive models,
including and excluding MMP9, will be assessed by the
estimates of sensitivity, specificity, proportion of false
positives and negatives and overall percentage of cor-
rect predictions. Receiver operating curves (ROC) and
area under the curve (AUC) of the ROC will be pre-
sented for each of the models, including and excluding
MMP9, as an indication and comparison of diagnostic
ability.
Bias and confounding factors
There will be duplicate determination of the serum MMP9
level and dual data entry. Information on potential con-
founders, for example injuries or chronic illnesses that
may lead to a raised serum MMP9, will be collected by the
research nurse. The analyses will be adjusted to take
account of any confounders or selection bias. All blood
samples will be analysed in the same laboratory to ensure
standardisation of measurement and reporting. The tech-
nician doing the MMP9 ELISA assay will be blinded to the
symptoms, signs or diagnosis of the patient.
Ethical approval
This study has been approved by the Black Country
Research Ethics Committee, 6th August 2007. REC refer-
ence number: 07/H1202/72.
Discussion
Colorectal cancer is a major cause of morbidity and mor-
tality. Most colorectal cancers arise from adenomas and
could be detected early by screening. The national bowel
cancer screening programme uses FOBt. Even though FOB
reduces mortality the test has high false positive rates.
Increased levels of an enzyme called matrix metalloprotei-
nase 9 (MMP9) has significant potential as a marker for
both adenomas and cancers, and this can be measured
from a blood sample. This study is to examine whether
using MMP9 as an adjunct to FOBt can improve the accu-
racy of screening and reduce the number of false positive
tests that cause anxiety and require invasive and poten-
tially harmful investigation.
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